CHIA-CHI LINCHIH-HUNG HSUYEONG-SHIAU PUVogelzang N.J.2020-04-282020-04-2820081464-4096https://www.scopus.com/inward/record.uri?eid=2-s2.0-40449121694&doi=10.1111%2fj.1464-410X.2007.07356.x&partnerID=40&md5=1991e24fc174ad187a60db7393c34464https://scholars.lib.ntu.edu.tw/handle/123456789/487341[SDGs]SDG3alpha interferon; anthracycline; carboplatin; cetuximab; cisplatin; docetaxel; doxorubicin; etoposide; fluoropyrimidine; fluorouracil; folinic acid; gefitinib; gemcitabine; ifosfamide; lapatinib; lonafarnib; methotrexate; navelbine; oxaliplatin; paclitaxel; panitumumab; pemetrexed; platinum; protein tyrosine kinase inhibitor; tipifarnib; trastuzumab; unindexed drug; vinblastine; vinflunine; add on therapy; bladder cancer; cancer combination chemotherapy; cancer surgery; cancer survival; cancer therapy; clinical trial; colorectal cancer; DNA repair; drug activity; drug efficacy; drug metabolism; drug potentiation; drug targeting; drug tolerability; excision repair; human; lung non small cell cancer; nephrotoxicity; neurotoxicity; neutropenia; priority journal; prognosis; protein expression; short survey; statistical significance; thrombocytopenia; transitional cell carcinoma; treatment response; urogenital tract carcinoma; urogenital tract tumor; vomiting; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Delivery Systems; Humans; Neoplasm Metastasis; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome; Urologic Neoplasmsjournal article10.1111/j.1464-410X.2007.07356.x180701932-s2.0-40449121694